Please assess the completion status of the following clinical trial:

Trial Title: Treatments for Psychogenic Nonepileptic Seizures (NES)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Video electroencephalogram (vEEG) confirmed diagnosis of NES~* Have at least one nonepileptic seizure per month~* Comorbid diagnosis of either depression, anxiety, or post traumatic stress disorder (PTSD)~* Able to complete self report symptom scales~* Not receiving optimized antidepressant medication~Exclusion Criteria:~* Equivocal electroencephalogram (EEG) findings~* Current suicidality, litigation, or self-mutilation~* Using monoamine oxidase inhibitors (MAOIs), pimozide, or sumatriptan~* Allergy/sensitivity to sertraline~* Current alcohol/drug dependence~* Serious medical illness requiring current hospitalization

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 95 Years
- Healthy Volunteers: f

Study Arms:
- sertraline (Type: ACTIVE_COMPARATOR): flexible dose sertraline, 25 to 200mg titration as tolerated, administered over 12 weeks with a two week untreated lead in period monitoring their baseline NES
- placebo (Type: PLACEBO_COMPARATOR): flexible dose placebo, administered over 12 weeks with a two week untreated lead in period monitoring their baseline NES

Based on this trial design, predict the completion outcome and termination type (if applicable).